With pos­i­tive PhI­II da­ta in hot flash­es, Bay­er is a step clos­er to chal­leng­ing Astel­las’ Veozah

Bay­er’s non-hor­mon­al drug can­di­date for hot flash­es in post­menopausal women has suc­ceed­ed in the last of a trio of reg­is­tra­tional tri­als, set­ting the stage for reg­u­la­to­ry fil­ings.

The Phase III OA­SIS 3 tri­al set elin­zane­tant against place­bo in post­menopausal women with va­so­mo­tor symp­toms or hot flash­es. The drug met the pri­ma­ry end­point, achiev­ing a sig­nif­i­cant re­duc­tion in the fre­quen­cy of mod­er­ate to se­vere hot flash­es at 12 weeks ver­sus place­bo, Bay­er said in a Tues­day re­lease.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.